GH Research PLC (NASDAQ:GHRS) Receives Average Rating of “Moderate Buy” from Brokerages

GH Research PLC (NASDAQ:GHRS) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $40.3750.

GHRS has been the topic of a number of recent analyst reports. Citigroup reissued an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Citizens Jmp decreased their target price on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research report on Friday, May 15th. Cantor Fitzgerald boosted their target price on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. HC Wainwright decreased their target price on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GHRS. Barclays PLC increased its holdings in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares in the last quarter. North Star Investment Management Corp. bought a new stake in GH Research during the 1st quarter worth approximately $31,000. Royal Bank of Canada increased its holdings in GH Research by 43.1% during the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after purchasing an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the 4th quarter worth approximately $38,000. Finally, Osaic Holdings Inc. increased its holdings in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares in the last quarter. 56.90% of the stock is owned by institutional investors.

GH Research Trading Up 4.2%

Shares of GHRS opened at $24.60 on Thursday. The company has a market capitalization of $1.69 billion, a PE ratio of -26.74 and a beta of 1.31. GH Research has a 12 month low of $11.32 and a 12 month high of $25.94. The stock’s 50-day moving average price is $21.32 and its two-hundred day moving average price is $17.14.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Equities research analysts predict that GH Research will post -1.46 EPS for the current fiscal year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.